Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
17.55
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pacira Pharm Inc
< Previous
1
2
3
4
5
6
Next >
Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner
April 20, 2023
PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer
April 19, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Analyst Expectations for Pacira BioSciences's Future
February 28, 2023
Via
Benzinga
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources
April 03, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures
March 29, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
March 27, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Earnings Preview For Pacira BioSciences
February 27, 2023
Via
Benzinga
Where Pacira BioSciences Stands With Analysts
January 31, 2023
Via
Benzinga
Pacira BioSciences's Return On Capital Employed Insights
November 23, 2022
Via
Benzinga
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
March 22, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
March 08, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
February 28, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions
February 23, 2023
Multi-year agreement will make Pacira’s medical device ioveraº the Official Non-Opioid Pain Management Partner of the LPGA
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
February 21, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
January 23, 2023
On Monday, 12 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
January 10, 2023
Tuesday's session saw 16 companies set new 52-week lows.
Via
Benzinga
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
January 05, 2023
EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Pacira BioSciences
Via
GlobeNewswire
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
December 13, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
December 13, 2022
On Tuesday, 49 companies hit new 52-week lows.
Via
Benzinga
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
December 13, 2022
EXPAREL sales were 99 percent and unit volumes were 104 percent of November 2021
From
Pacira BioSciences
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
November 16, 2022
On Wednesday, 70 companies set new 52-week lows.
Via
Benzinga
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
November 14, 2022
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present at Two Healthcare Conferences in November
November 08, 2022
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences: Q3 Earnings Insights
November 03, 2022
Pacira BioSciences (NASDAQ:PCRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Pacira BioSciences Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
October 20, 2022
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
October 13, 2022
-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September --
From
Pacira BioSciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.